Macura, Stanislava
Novo Nordisk (Denmark)
4 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 334
- Verified
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 188
- Verified
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 71
- Verified
Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with type 2 diabetes
Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., & Christiansen, J. S. (2016) · Diabetic Medicine
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 51
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free